Effectiveness of symptom map-based education in the management of premenstrual syndrome: a randomized controlled trial.

Arch Womens Ment HealthSep 15, 2026 (epub)
Clinical ResearchObstetrics & GynecologyOpen access

Ahsen Demirhan Kayacik, Kevser Ilcioglu

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a symptom map-based educational intervention for managing premenstrual syndrome (PMS) in 110 women. The intervention led to significantly lower pain (4.21 vs. 6.81) and stress levels (8.54 vs. 12.03) compared to the control group, particularly benefiting those with higher baseline symptom severity.

Key findings

  • Intervention group reported significantly lower pain levels (4.21 vs. 6.81, p < .001).
  • Stress levels were significantly reduced in the intervention group (8.54 vs. 12.03, p < .001).
  • Improvements in PMS-specific life satisfaction were noted, linked to reduced depressive symptoms.

Why it matters

Understanding effective non-pharmacological interventions for PMS can enhance patient care and support individualized management strategies, particularly for those with severe symptoms.

Source

PubMed · PMID 42742795Free full text on PubMed Central

Published in Arch Womens Ment Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.